---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066250"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:05:44.652483+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Erasca prioritizes pipeline, extends cash runway to H1 2026; FDA/EMA agree on Phase 3 naporafenib trial

## Summary
- FDA/EMA endorsed SEACRAFT-2 Phase 3 design for naporafenib+trametinib in NRASm melanoma; dual primary endpoints PFS and OS.
- Phase 1 data for ERAS-801 in rGBM: MTD 240 mg QD, safe, PK above 90% tumor growth inhibition; expansion cohorts enrolling.
- Deprioritized FLAGSHP-1 (ERAS-601+cetuximab), ERAS-5, ERAS-10; cash runway extended from H2 2025 to H1 2026.
- Key upcoming milestones: naporafenib Phase 1b data in RAS Q61X tumors (2H 2024), ERAS-007 combo data in BRAFm CRC (H2 2023–H1 2024).

## SEC filing metadata
- accession: 0000950170-23-066250
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/0000950170-23-066250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/eras-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066250
- JSON: https://secwatch.observer/filing/0000950170-23-066250.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.